VESSL Therapeutics Ltd.

VESSL Therapeutics Ltd. , based in Israel, specializes in regenerative medicine solutions using cutting-edge cell and gene-based technologies to address critical vascular conditions. Founded in 2000, VESSL Therapeutics operates from Yokneam Illit, Israel, focusing on innovative therapies for patients with vascular diseases. The company has secured a total of USD 16.

00 mn through its Series A funding round led by RunYoung Capital in April 2021, targeting the development of its unique therapies. The founder's history is not publicly detailed, and there are no mentions of subsidiaries or notable pivots in business strategy. VESSL Therapeutics specializes in advanced regenerative medicine solutions through its proprietary cell and gene-based technologies. The company’s primary offerings, MultiGeneAngio (MGA) and MultiGeneGraft (MGG), focus on treating vascular-related conditions, particularly in patients suffering from advanced peripheral arterial disease (PAD) and end-stage renal disease (ESRD).

MGA utilizes a patient’s own endothelial cells modified with specific genes to promote the formation of natural bypasses, thereby increasing blood flow to oxygen-starved muscles. MGG involves a biosynthetic vascular graft lined with the patient’s endothelial cells, aimed at providing a clot-resistant vessel for hemodialysis access. These products cater to patients for whom conventional therapies have failed or are unsuitable, addressing significant medical needs across North America and Europe, where the prevalence of PAD and ESRD is substantial. VESSL Therapeutics’ revenue model centers around the development and commercialization of its regenerative medicine products, particularly MGA and MGG, which are currently in various stages of clinical trials.

The company engages primarily in B2B transactions with healthcare providers, hospitals, and medical centers that treat patients with vascular diseases. Revenue is generated through agreements with healthcare institutions that utilize these technologies as part of their therapeutic offerings. Specific pricing plans for these products have not been disclosed, but the company aims to provide cost-effective solutions that reduce hospital stays and surgical interventions associated with PAD and ESRD. Overall, VESSL is positioned to deliver innovative therapies that address critical gaps in the existing treatment landscape, potentially leading to significant market opportunities.

In April 2021, VESSL Therapeutics Ltd. raised USD 16. 00 mn in Series A funding led by RunYoung Capital. The funds will be utilized to advance its cell and gene therapy regenerative medicine platform for patients with peripheral artery disease and dialysis access.

The company is focused on designing new products to enhance its offerings and aims to expand into new markets, specifically targeting North America and Europe by 2023.